Medscape |
---|
New Oral GLP-1 Agonist for Obesity, Type 2 Diabetes |
![]() SAN DIEGO, CA – Orforglipron, Eli Lilly's investigational oral daily nonpeptide glucagon-like peptide-1 (GLP-1) agonist that can be taken with or without food, appears comparable with other injectable and oral agents in the class for treating obesity and type 2 diabetes, suggest two new phase 2 studies. |
||
2023-06-24 Read more about this article in source |
-
The ‘Six Pillars of Brain Health’ offers a game plan to maintain cognitive function 04/25/2025
-
Avocados, cheese and nuts are high in calories but have big health benefits 04/25/2025
-
Perfecting the squat before trying a lunge can start you off on the right foot 04/25/2025